methocinnamox

04/19/2022 - "The Potential of Methocinnamox as a Future Treatment for Opioid Use Disorder: A Narrative Review."
01/01/2023 - "Behavioral pharmacology of methocinnamox: A potential new treatment for opioid overdose and opioid use disorder."
11/08/2023 - "Methocinnamox (MCAM) is a novel, long-acting opioid receptor antagonist that might be an effective treatment for opioid use disorder (i.e., preventing relapse and overdose). "
01/01/2019 - "This study explored the potential of a pseudoirreversible mu-opioid receptor antagonist [methocinnamox (MCAM)] as a treatment for opioid abuse by examining its capacity to attenuate the reinforcing effects of mu-opioid receptor agonists in rhesus monkeys. "
10/01/2020 - "The pseudoirreversible mu opioid receptor antagonist methocinnamox (MCAM) might be useful for treating opioid abuse and overdose. "

01/01/2023 - "Behavioral pharmacology of methocinnamox: A potential new treatment for opioid overdose and opioid use disorder."
01/01/2023 - "This paper describes a program of research characterizing a potent, selective, and long-lasting mu opioid receptor antagonist, methocinnamox, and evaluating its potential for treating opioid overdose and opioid use disorder. "
01/01/2021 - "This paper provides an overview of several presentations at that meeting that discussed emerging new approaches for treating opioid overdose, including the following: (1) intranasal nalmefene, a competitive, reversible opioid receptor antagonist with a longer duration of action than naloxone; (2) methocinnamox, a novel opioid receptor antagonist; (3) covalent naloxone nanoparticles; (4) serotonin (5-HT)1A receptor agonists; (5) fentanyl-binding cyclodextrin scaffolds; (6) detoxifying biomimetic "nanosponge" decoy receptors; and (7) antibody-based strategies. "

01/01/2021 - "Methocinnamox Reverses and Prevents Fentanyl-Induced Ventilatory Depression in Rats."
01/01/2023 - "Studies in rodents and nonhuman primates demonstrate that methocinnamox prevents and reverses opioid-induced ventilatory depression and selectively blocks opioid self-administration. "